Caffeine and Taurine from Energy Drinks—A Review
Read full paper →- Authors
- Tania Mihăiescu, Sabina Turti, Marius Souca, Raluca Muresan, Larisa Achim, Eftimia Prifti, Ionel Papuc, Camelia Munteanu, Sorin Marian Mârza
- Journal
- Cosmetics
- Year
- 2024
- Citations
- 13
TL;DR
This narrative review found that energy drinks containing caffeine and taurine produce mixed effects on skin health, cardiovascular function, sleep, and cognition—with benefits in some populations (e.g., improved exercise capacity in athletes, migraine relief in children) but clear harms in others (e.g., elevated blood pressure, liver and kidney damage, poor sleep quality in adolescents)—but the evidence is too weak and inconsistent to draw firm conclusions for personal experimentation.
What they tested
This is a narrative review, not an original experiment. The authors searched for and summarised previous studies (cross-sectional surveys, case series, and individual case reports) published between 2000 and 2023 that examined the effects of energy drinks—specifically their caffeine and taurine content—on skin health and related physiological outcomes. The "interventions" were various doses and combinations of caffeine and taurine from commercial energy drinks. Comparators were either placebo, no treatment, or baseline measurements. Outcome measures included:
**Skin health:** wound healing, oxidative stress markers in skin, inflammation
**Cardiovascular:** systolic blood pressure, heart palpitations, heart rate
**Metabolic:** serum uric acid, creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), alkaline phosphatase (ALP)
**Neurological:** sleep quality, headaches, cognition, vigilance, reaction time, anxiety
**Other:** exercise capacity, bone density (osteoporosis risk), nausea, stomach ulcers
The review did not test a single hypothesis but instead compiled findings across many different studies with different designs, populations, and outcomes.
Who was studied
The review aggregated data from multiple studies, so there is no single sample. Populations included:
**Children** (age not precisely defined, but implied as prepubescent, roughly <12 years)
**Adolescents** (age range not specified, but typically 12–18 years)
**Adults** (18+ years, including athletes and students)
**Athletes** (specific sport not mentioned, but tested in cold weather conditions)
**Students** (likely university-aged, setting not specified)
Sample sizes across the original studies ranged from single case reports (n=1) to cross-sectional surveys with hundreds of participants. The review does not report total pooled sample size. No specific demographics (sex, ethnicity, baseline health status) are provided beyond broad categories.
How they measured it
The review does not standardise measurement methods because it summarises disparate studies. However, based on the outcomes reported, the following instruments and metrics were used across the original research:
**Blood pressure:** Sphygmomanometer (systolic and diastolic readings)
**Serum biomarkers:** Blood draws analysed for uric acid, creatinine, BUN, ALT, ALP (units not reported, but standard clinical lab values)
**Sleep quality:** Self-reported questionnaires (specific instrument not named) and possibly actigraphy (not specified)
**Cognition:** Reaction time tests, vigilance tasks, attention tests (specific batteries not named)
**Exercise capacity:** Likely treadmill or cycle ergometer tests (duration and protocol not described)
**Skin health:** Wound healing assessed visually or via biopsy (not specified), oxidative stress markers (e.g., malondialdehyde, glutathione—not explicitly stated but implied)
**Headaches/migraines:** Self-report or clinical diagnosis
**Anxiety:** Self-report scales (not named)
The lack of standardised measurement across studies is a major weakness.
Methodology
### Study design
This is a **narrative literature review**—not a systematic review or meta-analysis. The authors searched for articles published between 2000 and 2023 using unspecified databases (likely PubMed, Scopus, or similar). They included "descriptive cross-sectional designs, case series, and individual case reports." No PRISMA guidelines, search strategy, inclusion/exclusion criteria, or quality assessment tools are reported. The review is qualitative: the authors summarise findings in prose without pooling data statistically.
### Why this design matters
A narrative review can identify broad trends, highlight conflicting findings, and suggest areas for future research. It is useful for generating hypotheses. However, it **cannot prove causation** because:
**No randomisation:** The original studies were observational (cross-sectional, case series, case reports). These designs cannot control for confounding variables. For example, people who drink energy drinks may also have poor diets, sleep less, or smoke—any of which could cause the observed health effects.
**No blinding:** Neither participants nor researchers were blinded to energy drink consumption in the original studies. Expectation effects (placebo/nocebo) are uncontrolled.
**No control group:** Many of the included studies lacked a proper control group (e.g., case reports describe a single person). Without a comparator, you cannot attribute changes to the intervention.
**Selection bias:** Case series and case reports are prone to reporting bias—only unusual or extreme cases get published. Cross-sectional surveys capture associations at one time point, not cause-and-effect.
**Publication bias:** The review likely over-represents positive or dramatic findings because negative or null results are less likely to be published.
### Duration
The review does not specify the duration of the original studies. Cross-sectional surveys capture a single time point. Case reports describe individual events over days to weeks. No long-term (years) prospective data are included.
### Statistical approach
No meta-analysis was performed. The authors report p-values or confidence intervals from the original studies only sporadically (and none are reproduced in the abstract). The review is purely descriptive.
### Major methodological weaknesses
**No systematic search strategy:** Cannot be replicated.
**No quality assessment:** Studies of varying rigour are given equal weight.
**Heterogeneous outcomes:** Skin health, cardiovascular, metabolic, neurological, and exercise outcomes are all lumped together without clear prioritisation.
**Conflicting findings presented without resolution:** For example, caffeine is said to both cause and treat migraines in children, but the review does not explain the discrepancy (dose? age? individual differences?).
**Industry funding not disclosed:** The review does not state whether the authors received funding from energy drink companies. This is a critical omission.
Key findings
Because this is a narrative review, findings are presented as qualitative summaries. The following are extracted from the abstract and text:
### Primary outcomes (skin health)
**Caffeine contributed to skin healing in adolescents** (no effect size, p-value, or comparator reported).
**Taurine helps shield the skin from damaging oxidative stress among students** (no quantitative data provided).
**Taurine causes positive effects on oxidative stress and inflammation in adolescents** (no numbers).
### Secondary outcomes
**Cardiovascular**
**Caffeine administration in low doses caused a risk of cardiovascular disease** (contradictory: "low doses" caused risk? No dose specified, no effect size).
**High systolic blood pressure** was reported in adolescents consuming excessive energy drinks (no specific mmHg increase given).
**Heart palpitations** were reported (frequency not quantified).
**Effects on the cardiovascular system could be worse if taurine and caffeine are combined** (no data on interaction magnitude).
**Metabolic / Organ damage**
**Chronic intake of energy drinks caused significant increases in serum levels of uric acid, creatinine, BUN, ALT, and ALP**, indicating kidney and liver injury (no specific values, no thresholds for "significant").
**Osteoporosis** risk was mentioned (no bone density data).
**Neurological / Sleep**
**Caffeine alone does not significantly decrease sleep as much as a taurine/high caffeine ratio** (no sleep metric, no effect size).
**A low taurine/caffeine ratio does not decrease sleep** (contradicts the previous point? Unclear).
**Poor sleep quality** was reported in adolescents (no PSQI or actigraphy data).
**Headaches and dulled cognition** in children (no cognitive test scores).
**Caffeine was effective in treating migraines in children** (no responder rate, no comparator).
**Vigilance, attention, and reaction time were all improved by caffeine consumption** (no effect sizes, no baseline comparison).
**Exercise / Other**
**Taurine supplementation improved exercise capacity in cold weather conditions** among athletes (no metric: time to exhaustion? VO2 max?).
**Taurine prevents obesity among children** (no BMI or body fat data).
**Agitation, nausea, anxiety, stomach ulcers** were reported in adolescents (frequencies not given).
Effect magnitude
Because the review provides almost no numerical data, effect magnitudes cannot be calculated. The authors use qualitative language ("significant increases," "positive effects," "improved") without reporting actual values. For someone running a self-experiment, this means the paper offers **no actionable effect sizes** to inform what a meaningful change would look like.
The closest to a quantitative statement is the claim about sleep: "caffeine alone does not significantly decrease sleep as much as a taurine/high caffeine ratio." But without knowing the baseline sleep duration, the caffeine dose, or the taurine dose, this is meaningless for practical application.
Limitations
### What the authors acknowledge
The abstract does not include a limitations section. The paper itself (not fully available in the abstract) may discuss limitations, but they are not stated here.
### What a critical reader would note
1. **No systematic methodology:** The review lacks a reproducible search strategy, inclusion/exclusion criteria, or quality assessment. This is a major flaw for any review claiming to summarise evidence.
2. **Heterogeneous and poorly defined populations:** "Children," "adolescents," "students," and "athletes" are broad categories with no age ranges, sex breakdowns, or baseline health status. Effects likely vary dramatically within these groups.
3. **Conflicting findings unresolved:** Caffeine is said to both cause and treat migraines in children. Energy drinks are said to both improve and impair sleep. The review does not attempt to resolve these contradictions by dose, timing, or individual differences.
4. **No dose-response data:** The review does not specify how much caffeine or taurine was consumed in the original studies. "Low doses" and "excessive consumption" are undefined. This makes the findings useless for designing a personal experiment.
5. **Outcome switching:** The review's stated purpose is skin health, but most findings are about cardiovascular, metabolic, neurological, and exercise outcomes. Skin health data are minimal and vague.
6. **Publication bias:** The review likely over-represents positive findings. Negative or null results from unpublished studies or grey literature are not included.
7. **Industry funding not disclosed:** Energy drink research is often funded by manufacturers. Without a disclosure statement, readers cannot assess potential bias.
8. **Small and unrepresentative samples:** Case reports (n=1) and small case series cannot be generalised. Cross-sectional surveys capture associations, not causation.
9. **No statistical synthesis:** Without meta-analysis, the review cannot estimate pooled effect sizes or assess heterogeneity.
10. **Language and journal:** Published in *Cosmetics*, a journal focused on cosmetic science, not clinical medicine or nutrition. The relevance to health outcomes may be limited.
Practical takeaways
For someone running their own n=1 experiment, this paper is **not a reliable guide** due to its methodological weaknesses and lack of quantitative data. However, the general themes can inform cautious exploration.
### What to test (specific intervention and dose)
**Caffeine alone:** Test a standard dose (e.g., 100–200 mg, equivalent to one small energy drink or 1–2 cups of coffee) taken at a fixed time (e.g., 8:00 AM).
**Taurine alone:** Test 500–1000 mg taurine (typical energy drink dose) taken at the same time.
**Combined:** Test the same doses together (e.g., 150 mg caffeine + 1000 mg taurine).
**Comparator:** Use a placebo (e.g., decaffeinated coffee + water) on alternating days.
### Minimum meaningful duration
**Sleep effects:** 7–14 days per condition (caffeine alone, taurine alone, combined, placebo) to account for adaptation and weekly variability.
**Cognitive effects:** 3–5 days per condition (reaction time and vigilance adapt quickly).
**Skin effects:** 4–8 weeks (skin turnover is ~28 days; wound healing requires longer).
**Cardiovascular effects:** 1–2 weeks (blood pressure changes can occur within days).
### What to measure (specific metrics)
**Sleep:** Use a sleep diary (bedtime, wake time, latency, awakenings) plus a wrist actigraph or sleep tracker (e.g., Oura Ring, Fitbit) for objective sleep duration and efficiency. Measure the same metric every night.
**Cognition:** Use a validated reaction time test (e.g., Psychomotor Vigilance Task, available free online) at the same time each day (e.g., 2 hours after caffeine).
**Blood pressure:** Take seated blood pressure at the same time each morning (before caffeine) and 1 hour after caffeine. Use a validated home monitor.
**Skin:** Take a standardized photo of the same skin area (e.g., inner forearm) under the same lighting daily. Use a redness/oxidation app (e.g., SkinVision) or simply note changes in a diary.
**Mood/anxiety:** Use a daily 0–10 scale for anxiety, agitation, and nausea.
**Exercise capacity:** If testing for athletes, measure time to exhaustion on a stationary bike or treadmill at a fixed workload, in a controlled temperature (cold vs. room temperature).
### Key confounds to control for
**Time of day:** Always take the intervention at the same time. Caffeine later in the day disrupts sleep.
**Baseline caffeine intake:** Avoid other caffeine sources (coffee, tea, soda, chocolate) during the experiment. If that is impossible, keep them constant.
**Sleep schedule:** Go to bed and wake up at the same times every day.
**Diet:** Keep meals, alcohol, and water intake consistent. Taurine is found in meat and fish—control for dietary taurine.
**Exercise:** Keep exercise type, duration, and intensity constant across conditions.
**Menstrual cycle (if applicable):** Hormonal fluctuations affect sleep, mood, and cardiovascular function. Run each condition across the same phase of the cycle (e.g., follicular phase only).
**Expectation effects:** Use a blinded placebo (e.g., identical capsules or drinks). Have someone else prepare them so you do not know which is which.
**Weather:** If testing exercise capacity, control ambient temperature. The review mentions cold weather effects—test in a consistent environment.
### What a positive result would look like
**Sleep:** A consistent difference of ≥15 minutes in sleep onset latency or ≥30 minutes in total sleep time between conditions, with less than 10% variability within each condition.
**Cognition:** A ≥10% improvement in reaction time (e.g., from 250 ms to 225 ms) or a ≥15% reduction in lapses (reaction times >500 ms) on the PVT.
**Blood pressure:** A consistent ≥5 mmHg difference in systolic blood pressure between conditions (the minimum clinically meaningful change).
**Skin:** Visible reduction in redness or faster wound healing (e.g., wound area decreases by ≥20% faster in one condition).
**Exercise:** A ≥5% improvement in time to exhaustion or power output at a fixed heart rate.
### Important caveat
Given the review's suggestion that **combining caffeine and taurine may worsen cardiovascular effects**, anyone with a history of hypertension, arrhythmia, or anxiety should consult a doctor before experimenting. Start with low doses (e.g., 50 mg caffeine + 500 mg taurine) and monitor for palpitations, chest pain, or severe anxiety. Stop immediately if these occur.
**Bottom line:** This paper is too vague and methodologically weak to guide a rigorous self-experiment. Use it only as a starting point for generating hypotheses, then design your own controlled trial with clear doses, consistent measurement, and a placebo control.